{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:07:26Z","timestamp":1793902046460,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570174"],"award-info":[{"award-number":["82570174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230005"],"award-info":[{"award-number":["82230005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.05.043","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:30:28Z","timestamp":1780587028000},"page":"1289.e1-1289.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Factors and Predictive Model of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"given":"Ming","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-7195","authenticated-orcid":false,"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2026.05.043_bib0001","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.jtct.2026.05.043_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101076","article-title":"Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"60","author":"M\u00fcskens","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2026.05.043_bib0003","series-title":"Holland-Frei Cancer Medicine","article-title":"Engraftment of allogeneic hematopoietic transplants","author":"Champlin","year":"2003"},{"key":"10.1016\/j.jtct.2026.05.043_bib0004","unstructured":"Wilton KM, Hasserjian RP The dynamics of engraftment after stem cell transplant: clonal expansion by chance. Accessed February 25, 2026. 10.1182\/hem.V20.6.202361."},{"issue":"7","key":"10.1016\/j.jtct.2026.05.043_bib0005","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.043_bib0006","first-page":"935","article-title":"Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation","volume":"91","author":"Larocca","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.043_bib0007","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbmt.2013.11.034","article-title":"CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies","volume":"20","author":"Klyuchnikov","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.043_bib0008","first-page":"642","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0009","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/bloodadvances.2021004537","article-title":"Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation","volume":"6","author":"Prabahran","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ajh.26903","article-title":"Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Tang","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.05.043_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1106464","article-title":"Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective analysis","volume":"14","author":"Servais","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.05.043_bib0012","article-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Bader","year":"2024"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.043_bib0013","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","article-title":"Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia \u2013 a FILO study","volume":"38","author":"Orvain","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/16078454.2022.2042064","article-title":"Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes","volume":"27","author":"Chen","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2026.05.043_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1651658","article-title":"Risk factors and prognosis of poor graft function after allogeneic hematopoietic stem cell transplantation in pediatric: a retrospective study","volume":"13","author":"Pang","year":"2025","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0016","first-page":"1875","article-title":"Risk factors of primary poor graft function after allogeneic hematopoietic stem cell transplantation in patients with myeloid malignancies","volume":"32","author":"Zhang","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.043_bib0017","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3324\/haematol.2011.044966","article-title":"Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient\/donor factors, transplant conditions and myelotoxic drugs","volume":"96","author":"Nakamae","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/tan.15300","article-title":"The impact of donor-specific anti-HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantation","volume":"103","author":"Liu","year":"2024","journal-title":"HLA"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.043_bib0019","first-page":"877.e1","article-title":"Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"27","author":"Shahzad","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41409-023-02125-x","article-title":"Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"59","author":"Al-Ramahi","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.043_bib0021","first-page":"01604","article-title":"CD34+-selected stem cell boost provides robust outcomes in patients with poor graft function","volume":"S2666-6367","author":"Metheny","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0022","first-page":"46.e1","article-title":"Durable engraftment and excellent overall survival after CD34-selected peripheral blood stem cell boost in pediatric patients with poor graft function following allogeneic stem cell transplantation","volume":"29","author":"Fraint","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.043_bib0023","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00277-019-03715-w","article-title":"Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation","volume":"98","author":"Sun","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.043_bib0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2018.08.004","article-title":"Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights","volume":"56","author":"Kong","year":"2019","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0025","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1128\/JVI.72.6.5006-5015.1998","article-title":"Cytomegalovirus inhibits the engraftment of donor bone marrow cells by downregulation of hemopoietin gene expression in recipient stroma","volume":"72","author":"Steffens","year":"1998","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0026","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-024-01612-y","article-title":"Increased Epstein\u2012Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation","volume":"17","author":"Kong","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.043_bib0027","first-page":"493.e1","article-title":"Donor-specific hla antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation","volume":"29","author":"Lima","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jtct.2026.05.043_bib0028","doi-asserted-by":"crossref","first-page":"1734705","DOI":"10.3389\/fimmu.2026.1734705","article-title":"Case Report: Dual impact of daratumumab in early T-cell precursor acute lymphoblastic leukemia -- consolidation therapy achieves remission and eliminates donor-specific HLA antibodies","volume":"17","author":"Wong","year":"2026","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.043_bib0029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/tan.15560","article-title":"Post-transplant de novo anti-HLA donor specific antibodies may contribute to poor graft function after haploidentical haematopoietic stem cell transplantation","volume":"103","author":"Ji","year":"2024","journal-title":"HLA"},{"issue":"18","key":"10.1016\/j.jtct.2026.05.043_bib0031","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/cells14181410","article-title":"Novel BCR-targeting fusion proteins for antigen-specific depletion of alloreactive b cells in antibody-mediated rejection","volume":"14","author":"Zhang","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.jtct.2026.05.043_bib0032","article-title":"Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0033","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/10428194.2021.1872072","article-title":"Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation","volume":"62","author":"Prabahran","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.043_bib0034","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-018-3278-9","article-title":"Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"97","author":"Shimomura","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.05.043_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893545","article-title":"Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty?","volume":"13","author":"Dekker","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.043_bib0036","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.043_bib0037","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.stem.2022.06.012","article-title":"Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging","volume":"29","author":"Bogeska","year":"2022","journal-title":"Cell Stem Cell"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:56:03Z","timestamp":1791528963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726004446"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.043","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Predictive Model of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}